WASHINGTON, D.C. (February 17, 2004) — Executives and scientists from leading biotech and pharmaceutical companies will discuss "The Promise of Personalized Medicine" Wednesday, Feb. 25, at the Waldorf=Astoria Hotel in New York City.
The session runs from 7:45 to 9:25 a.m. to lead off the second full day of the BIO CEO & Investor Conference, an event expected to attract more than 1,500 biotechnology and pharmaceutical executives, investors and journalists.
"The FDA last year began to prepare for the era of personalized medicine by proposing new regulations to encourage companies to share pharmacogenomic information with the agency," said Morrie Ruffin, BIO's vice president for business development. "At this session, we're bringing together executives and scientists from some of the leading companies in this field to share their insights."
Later that day, at the 5:30–7 p.m. closing reception, a group of biotech financial analysts and venture capitalists will provide "The Last Word" on the current climate for biotech investment.
"The industry rebounded spectacularly in 2003, and 2004 is off to a good start," said Ruffin. "At the closing session, some of biotechnology's most respected experts will provide an analysis of the current climate and a hint of what to expect for the rest of 2004."
In addition to these sessions, the Feb. 23–25 CEO & Investor Conference will feature:
- Keynote addresses from NIH Director Elias Zerhouni, M.D., and Richard F. Pops, chairman of BIO and CEO of Alkermes Inc.
- Focus sessions on platform technologies and on biotech development in targeted disease areas, including rheumatoid arthritis, cancer, infectious diseases, asthma and allergies, stroke, diabetes and liver disease.
- Presentations from more than 200 private and publicly held biotechnology companies and roundtable sessions on key business issues and industry trends.
For full conference details, visit www.bio.org/ceo.
Stephen C. Ferruolo, shareholder, Heller Ehrman White & McAuliffe LLP, will moderate "The Promise of Personalized Medicine." The panelists are Richard Dean, Ph.D., CEO, Xanthus Life Sciences, Inc.; Robert Lipshutz, Ph.D., senior vice president, Corporate Development, Affymetrix, Inc.; Brad Margus, CEO, Perlegen Sciences, Inc.; Patrice M. Milos, Ph.D., senior director, Pharmacogenomics, Clinical Biochemical Measurements and DNA Sequencing, Global Research and Development, Pfizer, Inc.; Toni Schuh, Ph.D., president & CEO, SEQUENOM, Inc.; and Kari Stefansson, M.D., Dr. Med., president, CEO, secretary and director, deCODE genetics.
Estelle J. Tsevdos, Ph.D., a partner at Kenyon & Kenyon, will moderate "The Last Word." The panelists are Peter Barrett, senior partner, Atlas Venture Boston; Karen Bernstein, Ph.D., chairman and editor-in-chief, BioCentury Publications Inc.; Sven Borho, partner, Orbimed Advisors, LLC; Dennis J. Purcell, managing director, Perseus/Soros BioPharmaceutical Fund LLC; and Andrew J. Weisenfeld, managing director, Banc of America Securities.
Registration is complimentary for credentialed news media and investors. Online registration for media is available through Feb. 18 at www.bio.org. Please note on-site registration will be open only to reporters and editors working full-time for print or broadcast news organizations with valid media credentials. All others must register in advance.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.